Cell and Gene Regulatory
-
In Case You Missed Them: Recapping The FDA's Recent Guidances For Cell And Gene Therapies
9/17/2026
I review 10 of the FDA’s guidances spanning the last 12 months, all of which aid cell and gene therapy companies to assure safety and efficacy of these medicines.
-
Cell & Gene Unscripted: Regulatory Affairs
9/17/2026
One platform, multiple payloads: how delivery systems can lower costs and boost access. Parexel experts break down the regulatory data that matters on Cell & Gene Unscripted.
-
Cell & Gene Unscripted: Pre-Clinical
9/17/2026
Regulatory modernization is progressing, but harmonization gaps remain. Parexel's Chris Learn & Liz Spehalski dive into pre-IND strategy and precision therapies on Cell & Gene Unscripted.
-
GLP-1 Peptides In Asia: Expanding Access And Opportunity
9/17/2026
Asia's growing role in the GLP-1 market presents new opportunities and challenges. Learn how regulatory preparedness, scalable manufacturing, and robust quality systems can enable growth.
-
Why You Should Measure Comparability Debt Before Ever Starting A Study
9/17/2026
When analytical capability and process understanding fail to keep pace with a drug candidate, the technical uncertainty creates debt that's difficult to pay down.
-
Forging The Future Of RNA Therapeutics Through Science, Systems And Scales
9/16/2026
RNA innovation is shifting from discovery to scalable development. Explore advances in delivery, manufacturing, analytics, regulation, and commercialization driving broader therapeutic impact.
-
Protocol Builder And Informed Consent Builder Version 2.0
9/16/2026
Built by research compliance experts, this platform streamlines the protocol-writing process through customizable templates, workflow tools, and collaboration support for research teams.
-
What FDA Inspectors Want From Your OOS File
9/16/2026
Read enough FDA warning letters and a pattern emerges: Investigators rarely cite a retest that was performed badly. They cite a retest that nobody justified in writing. Let's take a closer look.
-
New USP Guidelines, Standards Address Lentivirus Characterization
9/16/2026
The United States Pharmacopeia is rolling out new standards and tools to help manufacturers characterize fragile, complex lentiviral vectors.
-
Inside Kyverna's Autoimmune CAR T Platform Beyond SPS
9/16/2026
Kyverna's progress suggests that autoimmune CAR T's commercial viability will depend as much on manufacturing readiness and focused indication selection as on its potential to deliver durable, drug-free remission.